[HTML][HTML] Leukemic stem cells and therapy resistance in acute myeloid leukemia
P Stelmach, A Trumpp - Haematologica, 2023 - ncbi.nlm.nih.gov
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
[HTML][HTML] Leukemic stem cells and therapy resistance in acute myeloid leukemia
P Stelmach, A Trumpp - Haematologica, 2023 - haematologica.org
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
Leukemic stem cells and therapy resistance in acute myeloid leukemia
P Stelmach, A Trumpp - Haematologica, 2023 - pubmed.ncbi.nlm.nih.gov
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
Leukemic stem cells and therapy resistance in acute myeloid leukemia.
P Stelmach, A Trumpp - Haematologica, 2023 - europepmc.org
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
[HTML][HTML] Leukemic stem cells and therapy resistance in acute myeloid leukemia
P Stelmach, A Trumpp - Haematologica, 2023 - haematologica.org
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
Leukemic stem cells and therapy resistance in acute myeloid leukemia.
P Stelmach, A Trumpp - Haematologica, 2023 - europepmc.org
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …